Table 2.
Summary table of the most relevant cell-surface and serum markers analysed.
| Marker | Lymphocyte Subset | SD vs. EID | Stability (V1 vs. V2) |
|---|---|---|---|
| Total CD49d | CD4+
CD8+ CD19+ |
1334 vs. 1535 1191 vs. 1558 1158 vs. 1475 |
Good |
| CD49d saturation (%) | CD4+
CD8+ CD19+ |
72.31 vs. 63.82 68.97 vs. 55.91 73.74 vs. 58.30 |
Good |
| % CD49d | CD8+ CD27+ CD19+ DN |
25.24 vs. 41.20 34.58 vs. 50.94 |
Good Good |
| CD29 | All subpopulations | Poor | |
| β7-Integrin | All subpopulations | Good | |
| NTZ serum (ng/mL) | - | 47814 vs. 12490 | Marginal |
| sVCAM-1 (pg/mL) | - | 69341 vs. 97955 | Good |
DN: double negative; EID: extended interval dose; NTZ: natalizumab; SD: standard dose; sVCAM-1: soluble vascular cell adhesion molecule-1; V1/V2: visit 1/visit 2.